TCGA-QK-A8Z8-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.039041096
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.310
- FATTY_ACID_METABOLISM+0.230
- XENOBIOTIC_METABOLISM+0.220
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.210
- PROTEIN_SECRETION+0.200
- SPERMATOGENESIS+0.200
- OXIDATIVE_PHOSPHORYLATION+0.180
- PEROXISOME+0.180
- KRAS_SIGNALING_DN+0.160
- MTORC1_SIGNALING+0.150
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.560
- TNFA_SIGNALING_VIA_NFKB-0.480
- ANGIOGENESIS-0.470
- UV_RESPONSE_DN-0.410
- HYPOXIA-0.400
- INFLAMMATORY_RESPONSE-0.390
- TGF_BETA_SIGNALING-0.380
- IL2_STAT5_SIGNALING-0.370
- APICAL_JUNCTION-0.350
- HEDGEHOG_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OR-A5LS-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.874 |
| 2 | ERR2278846 | — | — | 0.822 |
| 3 | GSM5359425 | — | — | 0.819 |
| 4 | SRR8518209 | — | C | 0.810 |
| 5 | MDT-AP-1302 | Med | Medulloblastoma | 0.804 |
| 6 | TCGA-55-6972-01A-11R-1949-07 | — | cohortA2 | 0.803 |
| 7 | ERR2278863 | — | — | 0.796 |
| 8 | TCGA-D8-A1JN-01A-11R-A13Q-07 | — | C | 0.794 |
| 9 | SRR1317596 | GTEX | — | 0.794 |
| 10 | TCGA-78-7147-01A-11R-2039-07 | — | cohortA1 | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.070 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |